Nitrosamine impurities in medicines: what’s the risk?...
In simple terms, risk is the possibility of something bad happening. It’s the uncertainty around the consequences of an activity with respect to something that we value.
USP’s COVID-19 Vaccine Handling Toolkit is designed to help address the challenges nurses and other healthcare providers face every day in preparing, distributing and administering essential vaccines.
Access to quality raw materials and increased stakeholder collaboration are needed to help ensure availability of monoclonal antibody (mAb) treatments for COVID-19 in low- and middle-income countries (LMICs).
USP’s recently released COVID-19 Vaccine Handling Toolkit is helping to fill critical operational efficiency gaps that practice settings have identified in vaccine administration.
Another public health crisis looms in the wake of the COVID-19 pandemic.
Recent politicization of the COVID-19 vaccine development and approval process has led to a concerning loss of confidence in vital governmental institutions. Each day that goes by, the picture seems to grow darker. Politicians criticize scientists without cause.
COVID-19 is transforming our ways of thinking about the development, manufacture and delivery of critical medicines to patients around the world.
The scale and speed of the global vaccine research and development effort in response to COVID-19 is unprecedented.